Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Interleukins × Clear all
NCT00994643 2025-04-30

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

Thomas Jefferson University

Phase 2 Completed
11 enrolled 9 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT01883323 2019-11-08

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

University Health Network, Toronto

Phase 2 Completed
12 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡